Topic overview
Briefly
- A study from Karolinska Institutet found that patients with both atrial fibrillation and Alzheimer's disease treated with NOACs experienced slower cognitive decline.
- Patients on NOACs had a lower risk of death, stroke, blood clots, and fractures compared to those receiving no anticoagulant treatment.
- The findings suggest that newer anticoagulants may offer cognitive benefits, but patients should not change their medications based on this study alone.
What happened
In Sweden, researchers from Karolinska Institutet conducted a study examining the effects of blood-thinning medications on cognitive decline in patients with both atrial fibrillation and Alzheimer's disease. The study, published in the European Heart Journal, involved over 7,000 participants and tracked their cognitive function over time using the Mini-Mental State Examination (MMSE). The findings revealed that patients treated with newer blood thinners known as NOACs experienced a significantly slower rate of cognitive decline compared to those treated with the older drug warfarin or those who received no anticoagulant treatment at all.
The study highlighted that patients on NOACs saw their cognitive decline slow by just over 0.2 MMSE points per year. Additionally, these patients had a lower risk of death, stroke, blood clots, and fractures compared to those who did not receive any anticoagulant treatment. While warfarin was also associated with lower risks of death, stroke, and blood clots, it posed a higher risk of major bleeding compared to NOACs. This research suggests that the treatment could have a positive effect on cognition, potentially by improving blood flow and reducing small-scale damage in the brain.
Dr. Mohammad Bakhtiar, a general practitioner based in England, commented on the significance of the study, noting that the large sample size makes the findings difficult to dismiss. He emphasized the importance of this information for general practitioners when deciding between NOACs and warfarin for patients with Alzheimer's and atrial fibrillation. However, he cautioned that patients should not make any changes to their current medications based solely on this study's findings, as the relationship between NOACs and cognitive decline is not definitively established as causal.
The study's results contribute to the growing body of evidence linking atrial fibrillation and Alzheimer's disease, as these two conditions often occur together in older adults. The research underscores the need for further investigation into the potential cognitive benefits of newer anticoagulants in this patient population, as well as the importance of careful medication management in individuals with both conditions.
Comprehensive report
Full story,
in detail.
Trace the developments that led here, see how the story evolved, and understand the forces and wider context surrounding it.